Related Experiment Videos

Antiphospholipid syndrome in children

Tadej Avcin1

  • 1Department of Allergology, Rheumatology and Clinical Immunology, University Children's Hospital Ljubljana, University Medical Center, Ljubljana, Slovenia. tadej.avcin@kclj.si

Insights

Pediatric antiphospholipid syndrome (APS) involves hypercoagulation and non-thrombotic issues in children. Neonatal APS is rare, but maternal antibodies pose risks; long-term neurodevelopmental monitoring is advised.

Area of Science:

  • Pediatric Rheumatology
  • Hematology
  • Autoimmune Disorders

Background:

  • Antiphospholipid syndrome (APS) is the leading acquired hypercoagulation disorder in children.
  • Beyond thrombosis, antiphospholipid antibodies are linked to diverse non-vascular symptoms.

Purpose of the Study:

  • To review recent clinical advancements in neonatal and pediatric APS.
  • To highlight distinctions between pediatric and adult APS.

Main Methods:

  • Review of recent clinical literature on pediatric and neonatal antiphospholipid syndrome.
  • Comparative analysis of clinical and laboratory findings in pediatric APS.

Main Results:

  • Neonatal APS involves thrombosis from maternal antibodies; other risk factors are crucial.
  • Transplacental antibodies may cause neurodevelopmental changes, necessitating assessments.
  • Pediatric APS often presents with multiple antibody positivity, inherited thrombophilia, and non-thrombotic symptoms (hematological, skin, neurological).
  • Distinct clinical characteristics suggest subgroups within primary APS and secondary APS associated with autoimmune diseases.

Conclusions:

  • Ongoing research refines the understanding of pediatric APS.
  • Significant differences exist between pediatric and adult antiphospholipid syndrome presentations.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...